Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Roxadustat - FibroGen

Drug Profile

Roxadustat - FibroGen

Alternative Names: ASP 1517; AZD 9941; FG-4592

Latest Information Update: 28 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator FibroGen
  • Developer Astellas Pharma; AstraZeneca; FibroGen
  • Class Amides; Antianaemics; Carboxylic acids; Isoquinolines; Small molecules
  • Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered Anaemia
  • Discontinued Sickle cell anaemia

Most Recent Events

  • 20 Dec 2018 Efficacy data from three phase III trials (ANDES, HIMALAYAS, SIERRAS) in Anaemia (associated with chronic kidney disease) released by FibroGen
  • 17 Dec 2018 Registered for Anaemia in dialysis-dependent (DD) chronic kidney disease (CKD) patients in China (PO) - First global approval
  • 17 Dec 2018 AstraZeneca and FibroGen expect to launch roxadustat in China in the second half of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top